Researchers at the Salk Institute and Albert Einstein College of Medicine unveiled VIS-Fbs, an antigen-stabilizable fluorescent nanobody platform that lights up only when bound to target proteins in living cells and animals. The approach is designed to eliminate the constant “background glow” seen with conventional fluorescent nanobodies by degrading unbound probes. The team reports that binding stabilizes the VIS-Fbs and triggers fluorescence across a broad visible spectrum, enabling multicolor tracking of distinct proteins simultaneously. The work, detailed in Nature Methods, describes a VIS-Fb engineering strategy built around unstable fluorescent nanobodies that rapidly clear when targets are absent. Industry relevance is immediate for preclinical drug discovery and translational biology, where high-specificity live readouts can tighten target validation and reduce ambiguity in dynamic pathway studies.